Breast Imaging

What Imaging Is Best for Axillary Restaging After Neoadjuvant Chemotherapy?

·
What Imaging Is Best for Axillary Restaging After Neoadjuvant Chemotherapy?

It’s Tuesday afternoon in the surgical oncology clinic. Your patient, a 52-year-old woman with a previously diagnosed 3 cm, clinically node-positive breast cancer, has just completed her course of neoadjuvant chemotherapy (NAC). She tolerated it well, and the primary breast tumor is no longer palpable. Now, you need to plan her definitive surgery. The critical question is how her axillary lymph nodes responded to treatment, as this will determine whether she can undergo a sentinel lymph node biopsy or requires a full axillary lymph node dissection. This article details the American College of Radiology (ACR) guided workflow for imaging the axilla in this specific post-NAC, pre-surgical setting. For this scenario, the ACR designates axillary ultrasound as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for restaging the axilla in a female patient with a known diagnosis of breast cancer who has completed neoadjuvant chemotherapy and is now being evaluated for surgery. The key inclusion criteria are:

  • A primary breast tumor that was greater than 2 cm in size at initial diagnosis.
  • Clinically node-positive disease (cN+) confirmed by physical exam or imaging prior to starting chemotherapy.
  • Successful completion of a full course of neoadjuvant chemotherapy.

This workflow is designed to assess treatment response in the axilla to guide surgical planning. It is crucial to distinguish this scenario from others that require a different imaging approach. This guidance does not apply to:

  • Initial diagnosis: Patients with a newly diagnosed breast cancer who have not yet started any treatment. The initial staging of the axilla follows a different pathway.
  • Clinically node-negative patients: Women who were considered node-negative before starting neoadjuvant therapy have different pre-surgical evaluation needs.
  • New palpable axillary lump: A patient presenting with a new, undiagnosed lump in the axilla, without a known breast cancer diagnosis, requires a diagnostic workup, not a restaging evaluation.

Applying this workflow to the wrong clinical context can lead to inappropriate surgical decisions. The focus here is strictly on assessing nodal response after systemic therapy to de-escalate axillary surgery when possible.

What Diagnoses Are You Working Up in This Scenario?

In the post-neoadjuvant setting, the imaging “workup” is not for a new diagnosis but rather to determine the extent of residual disease. The primary goal is to differentiate between a complete response and persistent cancer in the lymph nodes, which directly impacts surgical management and prognosis. The key possibilities you are assessing are:

Pathologic Complete Response (pCR) in the Axilla: This is the ideal outcome, where neoadjuvant chemotherapy has successfully eradicated all viable cancer cells from the axillary lymph nodes. Identifying patients who have achieved pCR is the main driver for considering less invasive surgery, such as sentinel lymph node biopsy (SLNB) instead of a full axillary lymph node dissection (ALND).

Residual Nodal Disease: This is the most common finding, where some, but not all, of the cancer in the lymph nodes has been eliminated. The disease burden may be significantly reduced, with nodes shrinking in size and number, but viable tumor cells persist. Accurately identifying even minimal residual disease is critical, as these patients typically require an ALND to ensure clearance and proper staging.

Post-Treatment Changes Mimicking Disease: Chemotherapy induces inflammation, fibrosis, and necrosis within lymph nodes. These benign post-treatment changes can sometimes appear suspicious on imaging, causing nodes to remain enlarged or have an abnormal appearance. The imaging study must be able to help distinguish these benign changes from active residual malignancy, often requiring subsequent tissue sampling for confirmation.

Why Is Axillary Ultrasound the Recommended Study for This Presentation?

For restaging the axilla after neoadjuvant chemotherapy, the ACR finds axillary ultrasound (US) to be Usually Appropriate. Its effectiveness stems from its high spatial resolution, lack of ionizing radiation, and ability to guide concurrent biopsy, making it the cornerstone of pre-surgical evaluation in this context.

The primary strength of ultrasound is its ability to meticulously evaluate lymph node morphology. Sonographers can assess for features suggestive of residual malignancy, such as persistent cortical thickening (typically >3 mm), a rounded shape, or the continued absence of the normal fatty hilum. This detailed anatomical assessment is highly sensitive for detecting abnormal nodes that warrant further investigation. Perhaps most importantly, US provides real-time guidance for fine-needle aspiration (FNA) or core needle biopsy of any suspicious-appearing node. This is particularly crucial for performing a targeted axillary dissection (TAD), where a clip is often placed in the biopsy-proven positive node before NAC, and ultrasound is used to locate and biopsy that specific clipped node after treatment to confirm response.

Alternative imaging modalities are rated lower for this specific clinical question:

  • MRI breast without and with IV contrast is rated as May be appropriate. While breast MRI is excellent for evaluating tumor response in the breast itself and can visualize the axilla, its ability to characterize individual lymph nodes is not definitively superior to high-quality ultrasound. It is more costly, requires IV contrast, and is less practical for guiding a real-time biopsy of a specific node.
  • FDG-PET/CT skull base to mid-thigh is rated as Usually not appropriate for this indication. Although valuable for initial systemic staging, PET/CT has limitations in the post-NAC setting. Its spatial resolution is lower than ultrasound, making it difficult to detect small-volume residual disease. Furthermore, post-treatment inflammation can cause false-positive FDG uptake, reducing its specificity. It also involves a significant radiation dose (☢☢☢☢ 10-30 mSv), which is not justified when a non-radiation alternative like ultrasound is more effective for the specific clinical question.

The choice of axillary US is a clear example of selecting the right tool for the job. It directly answers the clinical question—is there evidence of residual nodal disease?—with no radiation exposure (RRL=O 0 mSv) and provides an immediate pathway to tissue confirmation.

What’s Next After Axillary US? Downstream Workflow

The results of the post-neoadjuvant axillary ultrasound directly guide the next steps in management, primarily concerning biopsy and surgical planning. The decision tree is straightforward and aimed at confirming the nodal status pathologically.

If the US identifies one or more suspicious nodes: The standard next step is a US-guided biopsy of the most abnormal-looking node. If a clip was placed in a node prior to chemotherapy, that clipped node should be the primary target for biopsy, regardless of its appearance. A positive biopsy confirms residual nodal disease. This finding generally makes the patient a candidate for a full axillary lymph node dissection (ALND) at the time of their breast surgery to ensure all remaining disease is cleared.

If the US shows normal-appearing or no suspicious nodes: This suggests a good response to chemotherapy, but imaging alone is not sufficient to rule out microscopic residual disease. In this case, the patient may be a candidate for a less invasive surgical approach. The current standard of care often involves a sentinel lymph node biopsy (SLNB) combined with a targeted axillary dissection (TAD), where the surgeon removes the previously clipped node along with the sentinel nodes. If pathology on these nodes is negative, the patient can avoid the morbidity of a full ALND.

If the US is indeterminate or the clipped node cannot be localized: In some cases, post-treatment changes can make interpretation difficult. If a suspicious node cannot be confidently biopsied percutaneously or a previously clipped node cannot be found with ultrasound, breast MRI (May be appropriate) may be considered to help localize it. The ultimate decision will be deferred to the surgeon, who may need to proceed with SLNB/TAD and rely on intraoperative findings and pathologic analysis to determine if a completion ALND is necessary.

Pitfalls to Avoid (and When to Get Help)

Navigating the post-neoadjuvant axillary evaluation requires careful coordination and attention to detail. Here are a few common pitfalls to avoid:

  • Not reviewing pre-NAC imaging: Always compare the post-treatment ultrasound with the initial pre-treatment studies to assess the degree of response and ensure the correct nodal basin is being evaluated.
  • Failing to communicate with the radiologist: The imaging order should clearly state the patient’s history, including the initial nodal status and the presence and location of a clipped lymph node. This context is vital for a targeted, high-yield exam.
  • Relying solely on imaging for surgical decisions: A normal-appearing axilla on ultrasound after NAC does not equal a pathologic complete response. The false-negative rate is significant, which is why surgical staging with SLNB/TAD remains essential.

If there is a discrepancy between clinical exam and imaging findings, or if a clipped node cannot be localized with standard techniques, escalate by discussing the case in a multidisciplinary tumor board meeting with the radiologist and surgeon to form a consensus plan.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a comprehensive overview of all clinical variants and imaging modalities related to the axilla, or to explore the tools used to make these recommendations, please refer to the following resources:

Frequently Asked Questions

Why isn’t PET/CT recommended for restaging the axilla after chemotherapy?

While excellent for initial staging, PET/CT is rated ‘Usually not appropriate’ for this specific pre-surgical restaging. Its spatial resolution is lower than ultrasound, meaning it can miss small-volume residual disease. Additionally, post-chemotherapy inflammation can cause false-positive results. Ultrasound provides superior morphological detail and allows for direct biopsy guidance without radiation exposure.

What if a clip was placed in a lymph node, but it now looks normal on ultrasound?

Even if the clipped node appears normal on ultrasound, it still must be addressed. A normal appearance does not rule out microscopic residual disease. The standard of care is typically to proceed with a targeted axillary dissection (TAD) to surgically remove the clipped node, often in combination with a sentinel lymph node biopsy (SLNB), for definitive pathologic evaluation.

Is breast MRI a reasonable alternative to axillary ultrasound in this scenario?

Breast MRI is rated ‘May be appropriate.’ It can be a useful adjunct, especially for evaluating the response of the primary tumor in the breast and providing a broader view of the axilla. However, for the specific task of evaluating nodal morphology and guiding a biopsy of a suspicious or clipped node, high-resolution ultrasound is generally considered more direct, cost-effective, and practical.

If the axillary ultrasound is negative, can the patient skip axillary surgery?

No. A negative or normal-appearing axillary ultrasound after neoadjuvant chemotherapy is encouraging, but it has a significant false-negative rate. It cannot reliably confirm a pathologic complete response. Surgical evaluation of the lymph nodes (typically with SLNB and/or TAD) is still required to pathologically confirm the nodal status and guide further treatment decisions.

Does this guidance apply to patients who were node-negative before chemotherapy?

No, this guidance is specifically for patients who were clinically node-positive (cN+) before starting neoadjuvant chemotherapy. The management and surgical approach for patients who were initially cN0 are different and follow a separate clinical pathway.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026